Pharmosa Biopharm Statistics
Total Valuation
Pharmosa Biopharm has a market cap or net worth of TWD 8.18 billion. The enterprise value is 6.56 billion.
Market Cap | 8.18B |
Enterprise Value | 6.56B |
Important Dates
The next estimated earnings date is Thursday, November 14, 2024.
Earnings Date | Nov 14, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Pharmosa Biopharm has 129.02 million shares outstanding. The number of shares has increased by 14.02% in one year.
Shares Outstanding | 129.02M |
Shares Change (YoY) | +14.02% |
Shares Change (QoQ) | +8.86% |
Owned by Insiders (%) | n/a |
Owned by Institutions (%) | 0.87% |
Float | 119.67M |
Valuation Ratios
The trailing PE ratio is 276.61.
PE Ratio | 276.61 |
Forward PE | n/a |
PS Ratio | 23.40 |
PB Ratio | 4.11 |
P/FCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 299.91, with an EV/FCF ratio of -70.16.
EV / Earnings | 236.05 |
EV / Sales | 20.23 |
EV / EBITDA | 299.91 |
EV / EBIT | n/a |
EV / FCF | -70.16 |
Financial Position
The company has a current ratio of 16.29, with a Debt / Equity ratio of 6.34.
Current Ratio | 16.29 |
Quick Ratio | 15.76 |
Debt / Equity | 6.34 |
Debt / EBITDA | 7.46 |
Debt / FCF | -1.35 |
Interest Coverage | -2.83 |
Financial Efficiency
Return on equity (ROE) is 2.11% and return on invested capital (ROIC) is -0.43%.
Return on Equity (ROE) | 2.11% |
Return on Assets (ROA) | -0.42% |
Return on Capital (ROIC) | -0.43% |
Revenue Per Employee | n/a |
Profits Per Employee | n/a |
Employee Count | n/a |
Asset Turnover | 0.22 |
Inventory Turnover | n/a |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -31.31% in the last 52 weeks. The beta is 0.52, so Pharmosa Biopharm's price volatility has been lower than the market average.
Beta (5Y) | 0.52 |
52-Week Price Change | -31.31% |
50-Day Moving Average | 60.83 |
200-Day Moving Average | 78.89 |
Relative Strength Index (RSI) | 53.10 |
Average Volume (20 Days) | 405,202 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Pharmosa Biopharm had revenue of TWD 324.12 million and earned 27.78 million in profits. Earnings per share was 0.23.
Revenue | 324.12M |
Gross Profit | 317.23M |
Operating Income | -9.85M |
Pretax Income | 27.78M |
Net Income | 27.78M |
EBITDA | -566,000 |
EBIT | -9.85M |
Earnings Per Share (EPS) | 0.23 |
Balance Sheet
The company has 1.75 billion in cash and 126.37 million in debt, giving a net cash position of 1.62 billion or 12.58 per share.
Cash & Cash Equivalents | 1.75B |
Total Debt | 126.37M |
Net Cash | 1.62B |
Net Cash Per Share | 12.58 |
Equity (Book Value) | 1.99B |
Book Value Per Share | 15.44 |
Working Capital | 1.70B |
Cash Flow
In the last 12 months, operating cash flow was 56.74 million and capital expenditures -150.19 million, giving a free cash flow of -93.45 million.
Operating Cash Flow | 56.74M |
Capital Expenditures | -150.19M |
Free Cash Flow | -93.45M |
FCF Per Share | -0.72 |
Margins
Gross margin is 97.87%, with operating and profit margins of -3.04% and 8.57%.
Gross Margin | 97.87% |
Operating Margin | -3.04% |
Pretax Margin | 8.57% |
Profit Margin | 8.57% |
EBITDA Margin | -0.17% |
EBIT Margin | -3.04% |
FCF Margin | -28.83% |
Dividends & Yields
Pharmosa Biopharm does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -14.02% |
Shareholder Yield | -14.02% |
Earnings Yield | 0.36% |
FCF Yield | -1.14% |
Stock Splits
This stock does not have any record of stock splits.
Last Split Date | n/a |
Split Type | n/a |
Split Ratio | n/a |